TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8146996
Drug: iodine brine
Normalized name: brine shrimp extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodine brine concentrate (2 x 100 ml, daily iodine uptake approximately 9 mg)
Study: 31615318
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + anti-inflammatory + purified micronized flavonoid fraction (Group 2)
Study: 31615318
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + anti-inflammatory + alpha-blocker (Group 1)
Study: 21996130
Drug: Malleable protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malleable protein matrix (MPM) from whey in low-fat yoghurt (150 g, two servings daily for 3 months)
Study: 21996130
Drug: Placebo yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo yoghurt (matching control, identical in protein content 15 g/d)
Study: 12895195
Drug: Cerivastatin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.2 mg daily)
Study: 10373050
Drug: C+E (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+E (5 mg . kg(‐1) caffeine + 1 mg . kg(‐1) ephedrine)
Study: 6407501
Drug: Fluvoxamine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (maximum 300 mg daily)
Study: 6407501
Drug: Imipramine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (maximum 200 mg daily)
Study: 24801219
Drug: CCRC (compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRC (compound Congrongyizhi Capsule) treatment
Study: 9688376
Drug: 0.5% ferric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ferric hyaluronate adhesion prevention gel
Study: 9688376
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (Control)
Study: 2684659
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia with morphine
Study: 2684659
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia without morphine
Study: 23688146
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for childhood anxiety
Study: 21855408
Drug: Evening bright
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening bright light exposure (∼4000 lux) for 45 minutes daily
Study: 21855408
Drug: Morning bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning bright light exposure (∼4000 lux) for 45 minutes daily
Study: 9169338
Drug: 6% crude
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% crude coal tar (CCT) ointment
Study: 8228797
Drug: tPA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA (100 mg 3 h‐1)
Study: 31703672
Drug: Estimation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimation of compounded medications expiration date
Study: 31703672
Drug: Commonly compounded
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly compounded dosage forms
Study: 31703672
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of sterile products
Study: 19938710
Drug: Goal-oriented infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goal-oriented infusion therapy with monitoring of central hemodynamic parameters and passive leg raising test
Study: 19938710
Drug: Standard infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard infusion therapy (a combination of colloids and crystalloids (1:1) at a rate of 6‐7 ml/kg/h)
Study: 17466815
Drug: Sequential Multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Multiple Assignment Randomized Trial (SMART)
Study: 15951872
Drug: Acute normovolemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute normovolemic hemodilution (ANH) - autologous blood 15 mL kg(‐1) withdrawn and replaced by 6% hydroxyethylstarch (HES)
Study: 15951872
Drug: Acute hypervolemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hypervolemic hemodilution (HHD) - HES administered without removal of any autologous blood
Study: 12831588
Drug: Single-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SD) protocol of cetrorelix (3 mg); n = 541
Study: 12831588
Drug: Multiple-dose (MD)
Normalized name: miconazole nitrate Topical Solution [Nail MD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose (MD) protocol of cetrorelix (0.25 mg/day); n = 1066
Study: 10382927
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 1 ml saline per nerve root sleeve (group A)
Study: 10382927
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml bupivacaine 0.5% combined with 40 mg methylprednisolone solution (group B)
Study: 10382927
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 40 mg methylprednisolone solution (group C)
Study: 8887586
Drug: Natural surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural surfactant treatment
Study: 6321673
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy and chemotherapy (group R, 76 patients)
Study: 6321673
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (group C, 88 patients)
Study: 6321673
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (group C)
Study: 3948591
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (preterm)
Study: 3948591
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (full-term)
Study: 18201212
Drug: Liraglutide 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.25 mg/day
Study: 18201212
Drug: Liraglutide 1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.9 mg/day
Study: 16771811
Drug: TAC and
Normalized name: Nystatin and Triamcinolone Acetonide Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC and steroids
Study: 10926623
Drug: Oral Salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Salbutamol (12 mg/day for 3 weeks)
Study: 4046137
Drug: Dietetic-hygienic measures,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic-hygienic measures, hypolipidemic agents (mainly probucol and clofibrate), antihypertensive agents (mainly diuretics and beta-blockers)
Study: 30010438
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine (Group 1)
Study: 30010438
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg morphine (Group 2)
Study: 20591813
Drug: Complete anaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete anaemia correction (haemoglobin target of 13 g/dL using darbepoetin alfa)
Study: 20591813
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with a haemoglobin rescue value of 9 g/dL)
Study: 7618662
Drug: Edrophonium (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.1, 0.3, 0.5, 0.7, 1.0, or 1.5 mg.kg‐1)
Study: 2694356
Drug: Active infrared
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active infrared laser therapy at 904 nm three times weekly for 2 weeks
Study: 122428
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg GnRH infusion
Study: 122428
Drug: 80 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg GnRH infusion
Study: 122428
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg GnRH infusion
Study: 122428
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg GnRH infusion in boys
Study: 122428
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy in boys
Study: 122428
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg GnRH infusion in men
Study: 30298560
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of ketoprofen lysine salt (KLS)
Study: 30298560
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of paracetamol/acetaminophen (P)
Study: 30298560
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ketoprofen lysine salt once a day for the first 3 days of activation
Study: 27358173
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg + 40 mg before PCI)
Study: 27358173
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg twice before PCI)
Study: 27358173
Drug: Rosuvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (5 mg) and ezetimibe (10 mg) twice before PCI
Study: 24809262
Drug: Noninvasive ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive ventilation (NIV) immediately after extubation in sequential group
Study: 22210658
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg s.c. once weekly for 36-52 weeks
Study: 7831635
Drug: Baker Norton
Normalized name: Bayer Aspirin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baker Norton metered dose inhaler with Volumatic
Study: 7831635
Drug: Ventolin metered
Normalized name: albuterol Metered Dose Inhaler [Ventolin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin metered dose inhaler with Volumatic
Study: 29852092
Drug: RT5 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT5 (5 times weekly)
Study: 29852092
Drug: RT3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT3 (3 times weekly)
Study: 29852092
Drug: RT2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT2 (2 times weekly)
Study: 21134243
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sotrastaurin
Study: 20137762
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg everolimus
Study: 20137762
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sotrastaurin and everolimus
Study: 20137762
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sotrastaurin with 2 mg everolimus
Study: 7589640
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg/d orally for 6 months
Study: 7589640
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy with E2 patches and medroxyprogesterone acetate
Study: 90965
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg atenolol daily from admission
Study: 31760780
Drug: Monitoring changes
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring changes in daily affect
Study: 31884935
Drug: Fast Dissolving
Normalized name: Mucinex Sinus-Max Day/Night Fast Dissolving Gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast Dissolving Tablets (FDT) of Febuxostat
Study: 27601592
Drug: Adjuvant cyclophosphamide-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant cyclophosphamide-based chemotherapy
Study: 27601592
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no systematic treatment)
Study: 17337369
Drug: Preemptive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive local infiltration (PLA) with 20 mL of 0.2% ropivacaine diluted with 80 mL of 0.9% saline (total volume 100 mL)
Study: 17337369
Drug: Postoperative wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative wound infiltration (POW) of 20 mL of 0.2% ropivacaine (40 mg)
Study: 15529256
Drug: Parenteral influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral influenza vaccination
Study: 11297828
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg (iv) morphine
Study: 10027666
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d. for two weeks
Study: 10027666
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg q.i.d. for two weeks
Study: 11583639
Drug: Oral antimicrobials
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antimicrobials
Study: 8085732
Drug: Topical antipseudomonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antipseudomonal agents
Study: 61340
Drug: Intravenous oxprenolol
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxprenolol
Study: 61340
Drug: Control studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control studies (no drug)
Study: 26355616
Drug: CO2 facial
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 facial treatment
Study: 17058830
Drug: Sodium ferulate
Normalized name: ferulate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferulate (SF) 300 mg/d intravenously for 4 weeks
Study: 17058830
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment including dietary therapy and hypodermic injection of insulin
Study: 14762655
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day for 12 months
Study: 11519354
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide cream (generic drug)
Study: 11519354
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide cream (brand name)
Study: 11519354
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control (no active treatment)
Study: 7853678
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) administered at a dose of 60-90 mg/kg divided into 3 dosages via 30-minute intravenous drip infusion
Study: 7853678
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) at a dose of 20 mg/kg via 30-minute intravenous drip infusion
Study: 7853678
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) at a dose of 10 mg/kg via 30-minute intravenous drip infusion
Study: 7853678
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) at doses of 20 and 10 mg/kg via 30-minute intravenous infusion
Study: 7853678
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) administered to patients with various infections
Study: 24649780
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (MgSO4) 50 mg kg(‐1) in 10 mL within 10 min, followed by an infusion of MgSO4 10 mg kg(‐1) hr(‐1) IV in 4mL for 12 hrs
Study: 20358154
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (MgSO4)
Study: 14701947
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg) and tinidazole (600 mg) combination twice daily for 7 days (Group 1)
Study: 14701947
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg), azithromycin (1 gm) and secnidazole (2 mg) as one time dose (Group 2)
Study: 14701947
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily) and metronidazole (200 mg thrice daily for 7 days (Group 3)
Study: 11124072
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine indices of benefit and harm
Study: 9070501
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dolasetron mesylate
Study: 9070501
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolasetron mesylate
Study: 9070501
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dolasetron mesylate
Study: 9070501
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dolasetron mesylate
Study: 8348504
Drug: Intravesical epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical epirubicin (50 mg per instillation)
Study: 8348504
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin (BCG) (150 mg per instillation)
Study: 2948430
Drug: Salbutamol (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.02 mL/kg of a 0.5% solution)
Study: 2948430
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (2 mL of a 0.025% solution)
Study: 2948430
Drug: Salbutamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol plus ipratropium combination
Study: 2948430
Drug: Half-dose or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose or full-dose combinations of salbutamol and ipratropium
Study: 25914397
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with zotarolimus-eluting stents
Study: 25917626
Drug: Phleum pratense
Normalized name: PHLEUM PRATENSE
DrugBank: Phleum pratense pollen (DB10394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phleum pratense subcutaneous immunotherapy (6 weekly doses)
Study: 25917626
Drug: Phleum pratense
Normalized name: PHLEUM PRATENSE
DrugBank: Phleum pratense pollen (DB10394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phleum pratense subcutaneous immunotherapy (8 weekly doses)
Study: 25917626
Drug: Phleum pratense
Normalized name: PHLEUM PRATENSE
DrugBank: Phleum pratense pollen (DB10394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phleum pratense subcutaneous immunotherapy (eight doses, two clustered increasing doses over 3 weeks)
Study: 20975274
Drug: Topiramate at
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate at a mean dose of 200 mg/day
Study: 20975274
Drug: Naltrexone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone at a mean dose of 50 mg/day
Study: 1414298
Drug: Sodium sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium sucrose sulphate solution
Study: 31499238
Drug: Hand gel
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL GEL [Hand Gel]
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand gel sanitizer
Study: 30423587
Drug: Placebo (physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physical therapies alone, n=112)
Study: 26420517
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill with sedative information
Study: 21987409
Drug: TachoSil (collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TachoSil (collagen patch coated with human coagulation factors)
Study: 12124856
Drug: Low-dose extract
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose extract of Tripterygium wilfordii Hook F (180 mg/day)
Study: 12124856
Drug: High-dose extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose extract of Tripterygium wilfordii Hook F (360 mg/day)
Study: 12124856
Drug: Open-label extension
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label extension (Low-dose)
Study: 12124856
Drug: Open-label extension
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label extension (High-dose)
Study: 10466239
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy with conventional regimens
Study: 7573018
Drug: Traditional Dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Dialysate (TD; ionized calcium concentration 1.75 mmol/L)
Study: 7573018
Drug: Low Calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Calcium Dialysate (LCD; ionized calcium concentration 1.25 mmol/L)
Study: 6783346
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 20 mg as a micronized powder with lactose
Study: 6783346
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 20 mg as micropellets without lactose